News About: Pharm. Industry
Health insurance should cover non-clinically effective generic products, KPMA says
The government is considering the conditional permit of some non-clinically effective generic drugs, but the Korea Pharmaceutical Manufacturers Association says that the clinical effectiveness of such drugs should be ...
Drugmakers urged to cut corrupt ties with doctors, pharmacists
It has long been a “common practice'' for drug manufacturers to provide rebates to hospitals, doctors and pharmacists in return for prescribing and dispensing their products.
There is no doubt that such rebates are...
Dongsung spend 54% of revenue on promotion in first quarter
Among the 45 pharmaceutical companies listed on the Korean Exchange, Dongsung Pharmaceutical turned out to be the biggest spender on promotion in the first quarter, according to data Yakup com., an information provide...
Leo Pharma eyes Korean pharmaceutical market
Leo Korea Pharma, a Korean unit of Leo Pharma, a global leader in dermatology and critical care, will initially market the company's psoriasis franchise (Xamiol) from July.
Xamiol gel (pronounced "zamiol"), contain...
Multinational firms to benefit from new drug reform
Most of foreign-invested drug firms are expected to increase their drug sales under the current system that has made doctors and pharmacists as well as pharmaceutical firms subject to punishment if they are found to h...
Dong-A, Daewoong increase market share
Dong-A Pharmaceutical and Daewoong Pharmaceutical have enjoyed the brisk sales of their flagship products, according to Yakup.com., an information provider.
Yakup.com said that Daewoong’s five products exceeded 10 ...
Pfizer to expand portfolio of generic medicines in Korea
Pfizer Korea is considering marketing medicines that are no longer patent protected, under its Established Products Business Unit strategy.
To this end, the company received Friday the approval of gemcitabine 200 m...
Dong-A to hit by drug price cut
Dong-A Pharmaceutical could lose up to 19 billion won in sales if the price of Stillen is reduced by 20 percent.
The Health Insurance Review Assessment and Service has recently announced that the insurance prices o...
Daewoong, Binex to join forces in R&D
Daewoong Pharmaceutical and Binex Co. have agreed to join hands to jointly develop new rheumatoid arthritis drug and biosimilars so that the two companies can stay competitive at home and abroad.
The two companies ...
HanAll to initiate Phase I study for oral human growth hormone
HanAll BioPharma said Monday that the Korea Food and Drug Administration approved the first clinical trial for oral human growth hormone (codename: HL-032).
The company plans to conduct its Phase I trial for HL-032...
